Target/Host (Institution) | Ligand | Target/Host Links | Ligand Links | Trg + Lig Links | Ki nM | ΔG° kJ/mole | IC50 nM | Kd nM | EC50/IC50 nM | koff s-1 | kon M-1s-1 | pH | Temp °C |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Plasma kallikrein (Homo sapiens (Human)) | BDBM335990![]() (4-(2-(3-(3-chlorophenyl)- 4,5-dihydroisoxazole-5- ...) | PDB Reactome pathway UniProtKB/SwissProt antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | 0.360 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Bristol-Myers Squibb Co. US Patent | Assay Description Plasma kallikrein determinations were made in 0.1 M sodium phosphate buffer at a pH of 7.5 containing 0.1-0.2 M sodium chloride and 0.5% PEG 8000. De... | US Patent US9738655 (2017) BindingDB Entry DOI: 10.7270/Q2BG2R3R | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM335779![]() (4-(2-(1-(3-chloro-2- fluorophenyl)-1H-1,2,3- triaz...) | PDB Reactome pathway UniProtKB/SwissProt antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | 0.460 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Bristol-Myers Squibb Co. US Patent | Assay Description Plasma kallikrein determinations were made in 0.1 M sodium phosphate buffer at a pH of 7.5 containing 0.1-0.2 M sodium chloride and 0.5% PEG 8000. De... | US Patent US9738655 (2017) BindingDB Entry DOI: 10.7270/Q2BG2R3R | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM335984![]() (4-(2-(1-(3-chloro-2- fluorophenyl)-1H-1,2,3- triaz...) | PDB Reactome pathway UniProtKB/SwissProt antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | 0.520 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Bristol-Myers Squibb Co. US Patent | Assay Description Plasma kallikrein determinations were made in 0.1 M sodium phosphate buffer at a pH of 7.5 containing 0.1-0.2 M sodium chloride and 0.5% PEG 8000. De... | US Patent US9738655 (2017) BindingDB Entry DOI: 10.7270/Q2BG2R3R | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM335977![]() (4-(2-(3-(3-chloro-2,6- difluorophenyl)-4,5- dihydr...) | PDB Reactome pathway UniProtKB/SwissProt antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | 0.640 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Bristol-Myers Squibb Co. US Patent | Assay Description Plasma kallikrein determinations were made in 0.1 M sodium phosphate buffer at a pH of 7.5 containing 0.1-0.2 M sodium chloride and 0.5% PEG 8000. De... | US Patent US9738655 (2017) BindingDB Entry DOI: 10.7270/Q2BG2R3R | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM335801![]() ((S)-4-(2-(1-(3-chloro-2- fluorophenyl)-1H-imidazol...) | PDB Reactome pathway UniProtKB/SwissProt antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | 0.920 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Bristol-Myers Squibb Co. US Patent | Assay Description Plasma kallikrein determinations were made in 0.1 M sodium phosphate buffer at a pH of 7.5 containing 0.1-0.2 M sodium chloride and 0.5% PEG 8000. De... | US Patent US9738655 (2017) BindingDB Entry DOI: 10.7270/Q2BG2R3R | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM335873![]() ((S)-N-(4-(1H-Pyrazol-4-yl)phenyl)-2-(1-(3-chloro-2...) | PDB Reactome pathway UniProtKB/SwissProt antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | 0.960 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Bristol-Myers Squibb Co. US Patent | Assay Description Plasma kallikrein determinations were made in 0.1 M sodium phosphate buffer at a pH of 7.5 containing 0.1-0.2 M sodium chloride and 0.5% PEG 8000. De... | US Patent US9738655 (2017) BindingDB Entry DOI: 10.7270/Q2BG2R3R | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM335755![]() ((S)-4-(2-(1-(3-Chloro-2-fluorophenyl)-1H-1,2,3-tri...) | PDB Reactome pathway UniProtKB/SwissProt antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | 1.08 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Bristol-Myers Squibb Co. US Patent | Assay Description Plasma kallikrein determinations were made in 0.1 M sodium phosphate buffer at a pH of 7.5 containing 0.1-0.2 M sodium chloride and 0.5% PEG 8000. De... | US Patent US9738655 (2017) BindingDB Entry DOI: 10.7270/Q2BG2R3R | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM335974![]() (4-(2-(3-(3-chloro-2- fluorophenyl)-4,5- dihydroiso...) | PDB Reactome pathway UniProtKB/SwissProt antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | 1.11 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Bristol-Myers Squibb Co. US Patent | Assay Description Plasma kallikrein determinations were made in 0.1 M sodium phosphate buffer at a pH of 7.5 containing 0.1-0.2 M sodium chloride and 0.5% PEG 8000. De... | US Patent US9738655 (2017) BindingDB Entry DOI: 10.7270/Q2BG2R3R | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM335799![]() (4-(2-(1-(3-chloro-2- fluorophenyl)-1H-imidazole- 4...) | PDB Reactome pathway UniProtKB/SwissProt antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | 1.21 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Bristol-Myers Squibb Co. US Patent | Assay Description Plasma kallikrein determinations were made in 0.1 M sodium phosphate buffer at a pH of 7.5 containing 0.1-0.2 M sodium chloride and 0.5% PEG 8000. De... | US Patent US9738655 (2017) BindingDB Entry DOI: 10.7270/Q2BG2R3R | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM335975![]() (4-(2-(3-(3-chlorophenyl)- 4,5-dihydroisoxazole-5- ...) | PDB Reactome pathway UniProtKB/SwissProt antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | 1.29 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Bristol-Myers Squibb Co. US Patent | Assay Description Plasma kallikrein determinations were made in 0.1 M sodium phosphate buffer at a pH of 7.5 containing 0.1-0.2 M sodium chloride and 0.5% PEG 8000. De... | US Patent US9738655 (2017) BindingDB Entry DOI: 10.7270/Q2BG2R3R | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM335982![]() (4-(2-(1-(3-chloro-2- fluorophenyl)-1H-1,2,3- triaz...) | PDB Reactome pathway UniProtKB/SwissProt antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | 1.34 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Bristol-Myers Squibb Co. US Patent | Assay Description Plasma kallikrein determinations were made in 0.1 M sodium phosphate buffer at a pH of 7.5 containing 0.1-0.2 M sodium chloride and 0.5% PEG 8000. De... | US Patent US9738655 (2017) BindingDB Entry DOI: 10.7270/Q2BG2R3R | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM335794![]() ((S)-4-(2-(1-(3-chloro-2- fluorophenyl)-1H-1,2,3- t...) | PDB Reactome pathway UniProtKB/SwissProt antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | 1.39 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Bristol-Myers Squibb Co. US Patent | Assay Description Plasma kallikrein determinations were made in 0.1 M sodium phosphate buffer at a pH of 7.5 containing 0.1-0.2 M sodium chloride and 0.5% PEG 8000. De... | US Patent US9738655 (2017) BindingDB Entry DOI: 10.7270/Q2BG2R3R | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM335871![]() (N-(4-(1H-Pyrazol-4-yl)phenyl)-2-(1-(3-chloro-2-flu...) | PDB Reactome pathway UniProtKB/SwissProt antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | 1.39 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Bristol-Myers Squibb Co. US Patent | Assay Description Plasma kallikrein determinations were made in 0.1 M sodium phosphate buffer at a pH of 7.5 containing 0.1-0.2 M sodium chloride and 0.5% PEG 8000. De... | US Patent US9738655 (2017) BindingDB Entry DOI: 10.7270/Q2BG2R3R | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM336111![]() (4-((S)-2-((R)-3-(3-Chloro-2-fluorophenyl)-4,5-dihy...) | PDB Reactome pathway UniProtKB/SwissProt antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | 1.40 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Bristol-Myers Squibb Co. US Patent | Assay Description Plasma kallikrein determinations were made in 0.1 M sodium phosphate buffer at a pH of 7.5 containing 0.1-0.2 M sodium chloride and 0.5% PEG 8000. De... | US Patent US9738655 (2017) BindingDB Entry DOI: 10.7270/Q2BG2R3R | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM335764![]() (4-((S)-2-((R)-3-(3-Chloro-2-fluorophenyl)-4,5-dihy...) | PDB Reactome pathway UniProtKB/SwissProt antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | 1.51 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Bristol-Myers Squibb Co. US Patent | Assay Description Plasma kallikrein determinations were made in 0.1 M sodium phosphate buffer at a pH of 7.5 containing 0.1-0.2 M sodium chloride and 0.5% PEG 8000. De... | US Patent US9738655 (2017) BindingDB Entry DOI: 10.7270/Q2BG2R3R | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM335874![]() (N-(4-(1H-Tetrazol-5-yl)phenyl)-2-(1-(3-chloro-2-fl...) | PDB Reactome pathway UniProtKB/SwissProt antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | 1.69 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Bristol-Myers Squibb Co. US Patent | Assay Description Plasma kallikrein determinations were made in 0.1 M sodium phosphate buffer at a pH of 7.5 containing 0.1-0.2 M sodium chloride and 0.5% PEG 8000. De... | US Patent US9738655 (2017) BindingDB Entry DOI: 10.7270/Q2BG2R3R | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM335870![]() ((S)-N-(4-Carbamoylphenyl)-2-(1-(3-chloro-2-fluorop...) | PDB Reactome pathway UniProtKB/SwissProt antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | 1.75 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Bristol-Myers Squibb Co. US Patent | Assay Description Plasma kallikrein determinations were made in 0.1 M sodium phosphate buffer at a pH of 7.5 containing 0.1-0.2 M sodium chloride and 0.5% PEG 8000. De... | US Patent US9738655 (2017) BindingDB Entry DOI: 10.7270/Q2BG2R3R | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM335797![]() ((S)-4-(2-(1-(3-chloro-2- fluorophenyl)-1H-pyrazole...) | PDB Reactome pathway UniProtKB/SwissProt antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | 1.79 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Bristol-Myers Squibb Co. US Patent | Assay Description Plasma kallikrein determinations were made in 0.1 M sodium phosphate buffer at a pH of 7.5 containing 0.1-0.2 M sodium chloride and 0.5% PEG 8000. De... | US Patent US9738655 (2017) BindingDB Entry DOI: 10.7270/Q2BG2R3R | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM336064![]() ((S)-4-(2-(1-(3-chloro-2- fluorophenyl)-1H-1,2,3-tr...) | PDB Reactome pathway UniProtKB/SwissProt antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | 1.82 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Bristol-Myers Squibb Co. US Patent | Assay Description Plasma kallikrein determinations were made in 0.1 M sodium phosphate buffer at a pH of 7.5 containing 0.1-0.2 M sodium chloride and 0.5% PEG 8000. De... | US Patent US9738655 (2017) BindingDB Entry DOI: 10.7270/Q2BG2R3R | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM336056![]() (4-(2-(3-(3-chloro-2- fluorophenyl)-4,5- dihydroiso...) | PDB Reactome pathway UniProtKB/SwissProt antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | 1.87 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Bristol-Myers Squibb Co. US Patent | Assay Description Plasma kallikrein determinations were made in 0.1 M sodium phosphate buffer at a pH of 7.5 containing 0.1-0.2 M sodium chloride and 0.5% PEG 8000. De... | US Patent US9738655 (2017) BindingDB Entry DOI: 10.7270/Q2BG2R3R | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM335993![]() (Ethyl 4-(2-(1-(3-chloro-2-fluorophenyl)-1H-1,2,3-t...) | PDB Reactome pathway UniProtKB/SwissProt antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | 1.96 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Bristol-Myers Squibb Co. US Patent | Assay Description Plasma kallikrein determinations were made in 0.1 M sodium phosphate buffer at a pH of 7.5 containing 0.1-0.2 M sodium chloride and 0.5% PEG 8000. De... | US Patent US9738655 (2017) BindingDB Entry DOI: 10.7270/Q2BG2R3R | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM336054![]() (4-(2-(3-(3-chloro-2- fluorophenyl)-4,5- dihydroiso...) | PDB Reactome pathway UniProtKB/SwissProt antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | 1.98 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Bristol-Myers Squibb Co. US Patent | Assay Description Plasma kallikrein determinations were made in 0.1 M sodium phosphate buffer at a pH of 7.5 containing 0.1-0.2 M sodium chloride and 0.5% PEG 8000. De... | US Patent US9738655 (2017) BindingDB Entry DOI: 10.7270/Q2BG2R3R | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM335878![]() (4-(5-(Aminomethyl)-2-(1-(3-chloro-2-fluorophenyl)-...) | PDB Reactome pathway UniProtKB/SwissProt antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | 2.29 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Bristol-Myers Squibb Co. US Patent | Assay Description Plasma kallikrein determinations were made in 0.1 M sodium phosphate buffer at a pH of 7.5 containing 0.1-0.2 M sodium chloride and 0.5% PEG 8000. De... | US Patent US9738655 (2017) BindingDB Entry DOI: 10.7270/Q2BG2R3R | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM335965![]() (4-(2-(1-(3-Chloro-2-fluorophenyl)-1H-1,2,3-triazol...) | PDB Reactome pathway UniProtKB/SwissProt antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | 2.34 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Bristol-Myers Squibb Co. US Patent | Assay Description Plasma kallikrein determinations were made in 0.1 M sodium phosphate buffer at a pH of 7.5 containing 0.1-0.2 M sodium chloride and 0.5% PEG 8000. De... | US Patent US9738655 (2017) BindingDB Entry DOI: 10.7270/Q2BG2R3R | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM335751![]() (4-(2-(1-(3-Chloro-2-fluorophenyl)-1H-1,2,3-triazol...) | PDB Reactome pathway UniProtKB/SwissProt antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | 2.40 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Bristol-Myers Squibb Co. US Patent | Assay Description Plasma kallikrein determinations were made in 0.1 M sodium phosphate buffer at a pH of 7.5 containing 0.1-0.2 M sodium chloride and 0.5% PEG 8000. De... | US Patent US9738655 (2017) BindingDB Entry DOI: 10.7270/Q2BG2R3R | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM336072![]() (4-((S)-2-((R)-3-(3-chloro-2- fluorophenyl)-4,5- di...) | PDB Reactome pathway UniProtKB/SwissProt antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | 2.44 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Bristol-Myers Squibb Co. US Patent | Assay Description Plasma kallikrein determinations were made in 0.1 M sodium phosphate buffer at a pH of 7.5 containing 0.1-0.2 M sodium chloride and 0.5% PEG 8000. De... | US Patent US9738655 (2017) BindingDB Entry DOI: 10.7270/Q2BG2R3R | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM335932![]() (4-(2-(1-(3-chloro-2- fluorophenyl)-1H-1,2,3- triaz...) | PDB Reactome pathway UniProtKB/SwissProt antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | 2.46 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Bristol-Myers Squibb Co. US Patent | Assay Description Plasma kallikrein determinations were made in 0.1 M sodium phosphate buffer at a pH of 7.5 containing 0.1-0.2 M sodium chloride and 0.5% PEG 8000. De... | US Patent US9738655 (2017) BindingDB Entry DOI: 10.7270/Q2BG2R3R | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM335812![]() ((S)-4-(2-(1-(3-chloro-2- fluorophenyl)-1H-1,2,3- t...) | PDB Reactome pathway UniProtKB/SwissProt antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | 2.57 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Bristol-Myers Squibb Co. US Patent | Assay Description Plasma kallikrein determinations were made in 0.1 M sodium phosphate buffer at a pH of 7.5 containing 0.1-0.2 M sodium chloride and 0.5% PEG 8000. De... | US Patent US9738655 (2017) BindingDB Entry DOI: 10.7270/Q2BG2R3R | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM336066![]() (4-((S)-2-((R)-3-(3-chloro-2- fluorophenyl)-4,5- di...) | PDB Reactome pathway UniProtKB/SwissProt antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | 2.63 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Bristol-Myers Squibb Co. US Patent | Assay Description Plasma kallikrein determinations were made in 0.1 M sodium phosphate buffer at a pH of 7.5 containing 0.1-0.2 M sodium chloride and 0.5% PEG 8000. De... | US Patent US9738655 (2017) BindingDB Entry DOI: 10.7270/Q2BG2R3R | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM335784![]() (4-(5-(6-aminopyridin-3- yl)-2-(1-(3-chloro-2- fluo...) | PDB Reactome pathway UniProtKB/SwissProt antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | 2.63 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Bristol-Myers Squibb Co. US Patent | Assay Description Plasma kallikrein determinations were made in 0.1 M sodium phosphate buffer at a pH of 7.5 containing 0.1-0.2 M sodium chloride and 0.5% PEG 8000. De... | US Patent US9738655 (2017) BindingDB Entry DOI: 10.7270/Q2BG2R3R | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM335809![]() ((S)-4-(2-(1-(3-chloro-2- fluorophenyl)-1H-imidazol...) | PDB Reactome pathway UniProtKB/SwissProt antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | 2.71 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Bristol-Myers Squibb Co. US Patent | Assay Description Plasma kallikrein determinations were made in 0.1 M sodium phosphate buffer at a pH of 7.5 containing 0.1-0.2 M sodium chloride and 0.5% PEG 8000. De... | US Patent US9738655 (2017) BindingDB Entry DOI: 10.7270/Q2BG2R3R | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM335868![]() (N-(4-Carbamoylphenyl)-2-(1-(3-chloro-2-fluoropheny...) | PDB Reactome pathway UniProtKB/SwissProt antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | 2.74 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Bristol-Myers Squibb Co. US Patent | Assay Description Plasma kallikrein determinations were made in 0.1 M sodium phosphate buffer at a pH of 7.5 containing 0.1-0.2 M sodium chloride and 0.5% PEG 8000. De... | US Patent US9738655 (2017) BindingDB Entry DOI: 10.7270/Q2BG2R3R | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM335785![]() (4-(2-(1-(3-chloro-2- fluorophenyl)-1H-1,2,3- triaz...) | PDB Reactome pathway UniProtKB/SwissProt antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | 2.81 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Bristol-Myers Squibb Co. US Patent | Assay Description Plasma kallikrein determinations were made in 0.1 M sodium phosphate buffer at a pH of 7.5 containing 0.1-0.2 M sodium chloride and 0.5% PEG 8000. De... | US Patent US9738655 (2017) BindingDB Entry DOI: 10.7270/Q2BG2R3R | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM335985![]() (4-(2-(5-amino-1-(3-chloro- 2-fluorophenyl)-1H- pyr...) | PDB Reactome pathway UniProtKB/SwissProt antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | 2.89 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Bristol-Myers Squibb Co. US Patent | Assay Description Plasma kallikrein determinations were made in 0.1 M sodium phosphate buffer at a pH of 7.5 containing 0.1-0.2 M sodium chloride and 0.5% PEG 8000. De... | US Patent US9738655 (2017) BindingDB Entry DOI: 10.7270/Q2BG2R3R | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM335762![]() (4-((S)-2-((R)-3-(3-Chloro-2-fluorophenyl)-4,5-dihy...) | PDB Reactome pathway UniProtKB/SwissProt antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | 3 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Bristol-Myers Squibb Co. US Patent | Assay Description Plasma kallikrein determinations were made in 0.1 M sodium phosphate buffer at a pH of 7.5 containing 0.1-0.2 M sodium chloride and 0.5% PEG 8000. De... | US Patent US9738655 (2017) BindingDB Entry DOI: 10.7270/Q2BG2R3R | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM335990![]() (4-(2-(3-(3-chlorophenyl)- 4,5-dihydroisoxazole-5- ...) | PDB Reactome pathway UniProtKB/SwissProt antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | 3.12 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Bristol-Myers Squibb Co. US Patent | Assay Description Plasma kallikrein determinations were made in 0.1 M sodium phosphate buffer at a pH of 7.5 containing 0.1-0.2 M sodium chloride and 0.5% PEG 8000. De... | US Patent US9738655 (2017) BindingDB Entry DOI: 10.7270/Q2BG2R3R | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM335881![]() (4-(2-(1-(3-Chloro-2-fluorophenyl)-1H-1,2,3-triazol...) | PDB Reactome pathway UniProtKB/SwissProt antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | 3.16 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Bristol-Myers Squibb Co. US Patent | Assay Description Plasma kallikrein determinations were made in 0.1 M sodium phosphate buffer at a pH of 7.5 containing 0.1-0.2 M sodium chloride and 0.5% PEG 8000. De... | US Patent US9738655 (2017) BindingDB Entry DOI: 10.7270/Q2BG2R3R | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM335804![]() ((S)-4-(2-(1-(3-chloro-2- fluorophenyl)-1H-1,2,3- t...) | PDB Reactome pathway UniProtKB/SwissProt antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | 3.24 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Bristol-Myers Squibb Co. US Patent | Assay Description Plasma kallikrein determinations were made in 0.1 M sodium phosphate buffer at a pH of 7.5 containing 0.1-0.2 M sodium chloride and 0.5% PEG 8000. De... | US Patent US9738655 (2017) BindingDB Entry DOI: 10.7270/Q2BG2R3R | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM336070![]() (4-((S)-2-((R)-3-(3-chloro-2- fluorophenyl)-4,5- di...) | PDB Reactome pathway UniProtKB/SwissProt antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | 3.24 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Bristol-Myers Squibb Co. US Patent | Assay Description Plasma kallikrein determinations were made in 0.1 M sodium phosphate buffer at a pH of 7.5 containing 0.1-0.2 M sodium chloride and 0.5% PEG 8000. De... | US Patent US9738655 (2017) BindingDB Entry DOI: 10.7270/Q2BG2R3R | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM335789![]() ((S)-4-(2-(1-(3-Chloro-2-fluorophenyl)-1H-1,2,3-tri...) | PDB Reactome pathway UniProtKB/SwissProt antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | 3.28 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Bristol-Myers Squibb Co. US Patent | Assay Description Plasma kallikrein determinations were made in 0.1 M sodium phosphate buffer at a pH of 7.5 containing 0.1-0.2 M sodium chloride and 0.5% PEG 8000. De... | US Patent US9738655 (2017) BindingDB Entry DOI: 10.7270/Q2BG2R3R | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM335753![]() (4-(2-(1-(3-Chloro-2-fluorophenyl)-1H-pyrazole-4-ca...) | PDB Reactome pathway UniProtKB/SwissProt antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | 3.37 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Bristol-Myers Squibb Co. US Patent | Assay Description Plasma kallikrein determinations were made in 0.1 M sodium phosphate buffer at a pH of 7.5 containing 0.1-0.2 M sodium chloride and 0.5% PEG 8000. De... | US Patent US9738655 (2017) BindingDB Entry DOI: 10.7270/Q2BG2R3R | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM335783![]() (4-(5-(2-aminopyridin-4- yl)-2-(1-(3-chloro-2- fluo...) | PDB Reactome pathway UniProtKB/SwissProt antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | 3.51 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Bristol-Myers Squibb Co. US Patent | Assay Description Plasma kallikrein determinations were made in 0.1 M sodium phosphate buffer at a pH of 7.5 containing 0.1-0.2 M sodium chloride and 0.5% PEG 8000. De... | US Patent US9738655 (2017) BindingDB Entry DOI: 10.7270/Q2BG2R3R | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM335860![]() ((S)-4-(2-(1-(3-Chloro-2-fluorophenyl)-1H-imidazole...) | PDB Reactome pathway UniProtKB/SwissProt antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | 3.84 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Bristol-Myers Squibb Co. US Patent | Assay Description Plasma kallikrein determinations were made in 0.1 M sodium phosphate buffer at a pH of 7.5 containing 0.1-0.2 M sodium chloride and 0.5% PEG 8000. De... | US Patent US9738655 (2017) BindingDB Entry DOI: 10.7270/Q2BG2R3R | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM336077![]() (4-((S)-2-((R)-3-(3-chloro-2- fluorophenyl)-4,5- di...) | PDB Reactome pathway UniProtKB/SwissProt antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | 4.15 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Bristol-Myers Squibb Co. US Patent | Assay Description Plasma kallikrein determinations were made in 0.1 M sodium phosphate buffer at a pH of 7.5 containing 0.1-0.2 M sodium chloride and 0.5% PEG 8000. De... | US Patent US9738655 (2017) BindingDB Entry DOI: 10.7270/Q2BG2R3R | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM335820![]() (4-(2-(1-(3-chloro-2- fluorophenyl)-1H-1,2,3- triaz...) | PDB Reactome pathway UniProtKB/SwissProt antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | 4.18 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Bristol-Myers Squibb Co. US Patent | Assay Description Plasma kallikrein determinations were made in 0.1 M sodium phosphate buffer at a pH of 7.5 containing 0.1-0.2 M sodium chloride and 0.5% PEG 8000. De... | US Patent US9738655 (2017) BindingDB Entry DOI: 10.7270/Q2BG2R3R | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM335973![]() (4-(2-(1-(3-chlorophenyl)- 1H-1,2,3-triazole-4- car...) | PDB Reactome pathway UniProtKB/SwissProt antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | 4.21 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Bristol-Myers Squibb Co. US Patent | Assay Description Plasma kallikrein determinations were made in 0.1 M sodium phosphate buffer at a pH of 7.5 containing 0.1-0.2 M sodium chloride and 0.5% PEG 8000. De... | US Patent US9738655 (2017) BindingDB Entry DOI: 10.7270/Q2BG2R3R | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM336040![]() (4-(2-(3-(3-chloro-2- fluorophenyl)-4,5- dihydroiso...) | PDB Reactome pathway UniProtKB/SwissProt antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | 4.36 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Bristol-Myers Squibb Co. US Patent | Assay Description Plasma kallikrein determinations were made in 0.1 M sodium phosphate buffer at a pH of 7.5 containing 0.1-0.2 M sodium chloride and 0.5% PEG 8000. De... | US Patent US9738655 (2017) BindingDB Entry DOI: 10.7270/Q2BG2R3R | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM335761![]() ((S)-4-(2-(1-(3-Chloro-2-fluorophenyl)-1H-1,2,3-tri...) | PDB Reactome pathway UniProtKB/SwissProt antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | 4.55 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Bristol-Myers Squibb Co. US Patent | Assay Description Plasma kallikrein determinations were made in 0.1 M sodium phosphate buffer at a pH of 7.5 containing 0.1-0.2 M sodium chloride and 0.5% PEG 8000. De... | US Patent US9738655 (2017) BindingDB Entry DOI: 10.7270/Q2BG2R3R | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM335810![]() (4-(2-(1-(3-chloro-2- fluorophenyl)-1H-1,2,3- triaz...) | PDB Reactome pathway UniProtKB/SwissProt antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | 4.70 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Bristol-Myers Squibb Co. US Patent | Assay Description Plasma kallikrein determinations were made in 0.1 M sodium phosphate buffer at a pH of 7.5 containing 0.1-0.2 M sodium chloride and 0.5% PEG 8000. De... | US Patent US9738655 (2017) BindingDB Entry DOI: 10.7270/Q2BG2R3R | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM336052![]() (4-(2-(1-(3-chloro-2- fluorophenyl)-1H-1,2,3-triazo...) | PDB Reactome pathway UniProtKB/SwissProt antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | 4.87 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Bristol-Myers Squibb Co. US Patent | Assay Description Plasma kallikrein determinations were made in 0.1 M sodium phosphate buffer at a pH of 7.5 containing 0.1-0.2 M sodium chloride and 0.5% PEG 8000. De... | US Patent US9738655 (2017) BindingDB Entry DOI: 10.7270/Q2BG2R3R | |||||||||||
More data for this Ligand-Target Pair |
Displayed 1 to 50 (of 635 total ) | Next | Last >> |